Menopausal Hot Flashes Market By Treatment Type (Hormonal Therapies, Non-Hormonal Therapies); By Drug Class (Estrogen-Only Therapy, Estrogen–Progestogen Therapy, Neurokinin Receptor Antagonists, SSRIs and SNRIs, Anticonvulsants, Anticholinergic Drugs, Other Therapies); By Route of Administration (Oral, Transdermal, Topical, Intranasal); By Application (Natural Menopause-Related Vasomotor Symptoms, Treatment-Induced Vasomotor Symptoms); By End User (Hospitals, Gynaecology and Menopause Clinics, Primary Care Centres, Oncology Clinics); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Menopausal Hot Flashes Market : Multi-Year Symptom Persistence Builds a Billion Prescription Opportunity

The Global Menopausal Hot Flashes Market was valued at USD 6.85 billion in 2025 and is projected to reach USD 10.44 billion by 2032, expanding at a CAGR of 6.2% during 2026–2032, according to Strategic Market Research.

 

Menopausal hot flashes, also known as vasomotor symptoms, are among the most common and disruptive symptoms experienced during menopause. Current treatment options include several FDA-approved hormonal and non-hormonal therapies. Although hormone therapy remains highly effective, its use may be limited by contraindications, safety concerns, or patient preference. As a result, research and development efforts are increasingly focused on safer, non-hormonal alternatives. Recent therapeutic pipelines are particularly targeting neural pathways within the brain’s thermoregulatory centre, offering a more precise approach to symptom management.

 

Hormone Therapy Retains the Volume Crown as Prescribing Momentum Returns

Menopausal hormone therapy remains the most effective pharmacological treatment for bothersome hot flashes. Systemic estrogen can be prescribed alone for women without a uterus, while women with a uterus generally receive estrogen with a progestogen to protect the endometrium. Product choice includes oral and transdermal formulations, but the important market distinction is whether patients are considered suitable for systemic hormone treatment.

Public data show that hormone therapy continues to have the highest prescription use among menopause treatments. According to the FDA, around 2 million U.S. women aged 46–65 received prescriptions for systemic estrogen alone or estrogen combined with progestogen in 2020. Although these prescriptions were not used only for hot flashes, the data provide a strong indication of the high demand for menopause medicines among women in this age group.

UK provides a more recent volume benchmark. NHS Business Services Authority data show that 14.7 million hormone replacement therapy items were prescribed to an estimated 2.8 million identified patients in 2024/25, equal to approximately 5.25 prescription items per patient during the year. Prescription items increased by 11% from the previous year, while the number of patients increased by 6.4%. Item growth therefore exceeded patient growth by 4.6 percentage points, indicating that longer treatment duration, repeat dispensing and formulation switching contributed alongside new patient additions.

Estradiol 0.06% gel alone accounted for 1.3 million prescription items, representing approximately 8.8% of all HRT items dispensed in UK during 2024/25. The formulation recorded annual growth of 13%, two percentage points above the overall HRT item growth rate. This gives transdermal and topical systemic estradiol an increasingly important position within the broader hormone therapy subsegment.

These figures show that the established hormone pathway is still expanding in some public healthcare systems. Growth is being supported by greater menopause awareness, more consultations and wider use of different formulations rather than by a single new branded product.

The U.S. market has followed a different historical pattern. Nationally representative data found that menopausal hormone therapy use fell from 26.9% of postmenopausal women in 1999–2000 to 4.7% in 2019–2020. This represents a decline of 22.2 percentage points, or approximately 82.5% relative to the earlier utilisation level. Usage also differed substantially by insurance status and racial and ethnic group, indicating that clinical demand does not convert evenly into prescriptions.

FDA-approved labelling changes in February 2026 could affect this pathway. Risk statements relating to cardiovascular disease, breast cancer and probable dementia were removed from the boxed warnings of six menopausal hormone therapy products. The endometrial cancer warning was not removed from systemic estrogen-only products. These changes may reduce some of the perceived barriers surrounding hormone therapy and strengthen the revenue outlook for established oral, patch and gel formulations.

For drug manufacturers, the renewed hormone discussion creates both opportunity and substitution risk. Established hormone suppliers may benefit from improved patient and prescriber confidence, while premium nonhormonal drugs will have to demonstrate value in clearly defined patients rather than relying only on general concern about hormones.

 

Neurokinin Therapies Redraw the Premium Nonhormonal Treatment Landscape

The most important commercial change has been the approval of therapies that act on neurokinin signalling in the brain’s temperature-control pathway. These medicines address vasomotor symptoms without replacing estrogen, creating a distinct branded category for patients who cannot, should not or prefer not to use hormone therapy.

Astellas established this segment when the FDA approved Veozah, or fezolinetant, in May 2023. Fezolinetant is an NK3 receptor antagonist approved for moderate-to-severe vasomotor symptoms due to menopause. Its approval introduced a drug developed specifically around the biological pathway associated with temperature dysregulation rather than repurposing an antidepressant or another established medicine.

Early utilisation translated into measurable commercial revenue. FDA estimated that approximately 28,700 patients received Veozah through U.S. outpatient retail pharmacies in May 2024. Astellas subsequently reported global VEOZAH sales of ¥46.6 billion in FY2025, an increase of ¥12.8 billion from ¥33.8 billion in FY2024. The reported annual revenue growth rate of 37.7% substantially exceeded the overall menopausal hot flashes market CAGR of 6.2%, reflecting the rapid early expansion of the premium neurokinin subsegment from a comparatively small commercial base.

U.S. VEOZAH revenue reached USD 269 million during FY2025, making the United States the most clearly disclosed national revenue market for the product. These figures confirm that neurokinin-targeted medicines have progressed from a clinical-development opportunity into a material branded prescription category.

Bayer ended Astellas’s single-product position when the FDA approved Lynkuet, or elinzanetant, on 24 October 2025. Lynkuet is the first FDA-approved dual NK1 and NK3 receptor antagonist for moderate-to-severe vasomotor symptoms due to menopause and became available in the United States in November 2025. Astellas effectively held the approved U.S. neurokinin category alone before Bayer’s market entry, giving VEOZAH a substantial first-mover advantage in prescriber familiarity and formulary contracting.

The European indication gives Bayer an additional competitive angle. The European Medicines Agency authorised Lynkuet for vasomotor symptoms associated with menopause and for symptoms caused by adjuvant endocrine therapy for breast cancer. This creates a defined specialist-care subsegment among patients receiving estrogen-suppressing cancer treatment, for whom systemic hormone therapy may be unsuitable.

Competition between Astellas and Bayer is likely to move beyond efficacy claims. Formulary placement, insurer restrictions, patient-support programmes, monitoring requirements and prescriber familiarity will influence which product gains share. A second neurokinin entrant also gives payers greater ability to negotiate coverage terms and reduces the first-mover advantage previously held by Astellas.

 

Low-Cost Alternatives Keep Payers in Control of Treatment Sequencing

Neurokinin drugs compete with a much older and less expensive group of nonhormonal prescription options. Low-dose paroxetine mesylate, sold as Brisdelle, is FDA approved specifically for moderate-to-severe vasomotor symptoms. Other SSRIs and SNRIs, including venlafaxine, escitalopram and conventional paroxetine products, are commonly used off-label. Gabapentin and oxybutynin also remain established alternatives in selected patients.

This distinction matters commercially. Brisdelle is an approved menopause product, while the wider SSRI and SNRI category largely consists of inexpensive medicines originally developed for other indications. These products give payers a low-cost treatment step before authorising premium neurokinin therapies.

NICE’s 2026 resource-impact assumptions illustrate the pricing gap. The estimated annual medicine acquisition cost was £627.20 for fezolinetant, compared with £17.22 for paroxetine, £37.83 for venlafaxine and £34.44 for oxybutynin. Fezolinetant’s annual acquisition cost was therefore approximately 36 times the paroxetine cost, 17 times the venlafaxine cost and 18 times the oxybutynin cost used in the NICE model.

The large difference between branded and generic treatment costs explains why reimbursement bodies may reserve neurokinin therapies for selected patients. Hormone products and repurposed generics account for the lower-priced, volume-driven portion of the treatment pathway. Neurokinin drugs generate substantially higher revenue per treated patient but operate within a smaller and more tightly managed population.

 

Reimbursement Gateways Decide Which Eligible Patients Convert into Revenue

The 30% share implies a broader modelled eligible population of approximately 1.22 million women, with the HRT-unsuitable segment forming the most commercially relevant public reimbursement pool for fezolinetant. This structure gives the branded nonhormonal category a meaningful addressable base while keeping access narrower than the full moderate-to-severe symptom population.

U.S. Veterans Affairs criteria demonstrate an even more sequenced approach. Eligibility for fezolinetant requires moderate-to-severe symptoms and a contraindication, intolerance or preference to avoid hormone therapy. The criteria also require inadequate response, intolerance or contraindication to another nonhormonal treatment.

Such conditions reduce the number of patients who can begin premium therapy immediately. They also lengthen the treatment journey because patients may have to try lower-cost medicines first. Manufacturers must consequently support formulary inclusion, prescriber education and patient navigation rather than treating approval as the end of commercial development.

Safety monitoring adds another layer of access friction for fezolinetant. The FDA added a warning in September 2024 concerning rare but serious liver injury and added a boxed warning in December 2024. Current instructions require liver testing before treatment, monthly during the first three months and again at months six and nine. Monitoring increases the burden on patients and clinical practices and gives competing products an opportunity to differentiate through convenience or safety positioning.

 

Pipeline Innovation Moves Toward On-Demand and Oncology-Linked Treatment

Vistagen is developing PH80, now also referred to as refisolone, as an investigational nonhormonal nasal spray. The company is positioning it as an as-needed, non-systemic treatment rather than another daily oral medicine. Vistagen has reported positive findings from a small exploratory Phase 2a study and has been preparing the U.S. investigational new drug programme needed for further Phase 2 development. Its commercial relevance lies in the possibility of creating an on-demand treatment subsegment rather than directly competing only for daily oral prescriptions.

Q-122 has been studied as a nonhormonal oral treatment for women experiencing vasomotor symptoms while taking tamoxifen or aromatase inhibitors after breast cancer. A randomised Phase 2 study reported reductions in symptom frequency and severity, supporting further development in a patient group where hormone therapy can be difficult to use. This oncology-related population could become a differentiated subsegment as nonhormonal treatment demand increases among women receiving endocrine therapy.

PhytoSERM is a plant-derived formulation designed to act selectively on estrogen-related pathways. Phase 2 studies have investigated its effect on menopausal hot flashes and brain health. The programme represents interest in treatments positioned between conventional hormone therapy and fully nonhormonal neurokinin drugs, but its clinical and commercial maturity remains below that of the approved prescription products.

 

Regional Growth Follows the Economics of Access, Coverage and Prescribing

The United States provides the clearest evidence of branded nonhormonal revenue because both Veozah and Lynkuet are approved and commercially available. VEOZAH generated USD 269 million in U.S. revenue during 2025, giving North America the strongest disclosed commercial position within the emerging neurokinin category. The U.S. opportunity remains constrained by fragmented insurance coverage, patient cost exposure and payer requirements.

UK offers the strongest public evidence of recurring prescription volume. Its 14.7 million HRT items and 11% annual item growth demonstrate a large and expanding established pathway, while NICE’s fezolinetant recommendation creates a managed route for the 30% HRT-unsuitable share of the eligible population.

The European Union now has two authorised neurokinin therapies and a differentiated Lynkuet indication covering endocrine-therapy-related symptoms. Moderate-to-severe vasomotor symptoms have been reported among 40% of surveyed European women, compared with 34% in the United States. Commercial performance will vary by country because national health technology assessments, reimbursement decisions and prescribing rules determine adoption after central regulatory approval.

Japan requires separate commercial assumptions. The WARM survey reported moderate-to-severe vasomotor symptoms in 16% of surveyed Japanese women. The reported rate was 18 percentage points below the United States and 24 percentage points below Europe, indicating a smaller reported severity pool before treatment-seeking and reimbursement differences are considered.

 

Competition Shifts from Drug Availability to Reimbursed Patient Capture

The menopausal hot flashes market no longer lacks pharmaceutical options. Hormone therapy provides the most effective established route, low-cost nonhormonal medicines give payers inexpensive alternatives and two branded neurokinin drugs now compete for premium prescriptions.

Astellas enters this phase with first-mover recognition, Bayer brings a dual-receptor product, a broad international launch programme and an EU indication that reaches endocrine-therapy-related symptoms. Generic suppliers retain influence because their acquisition costs remain between approximately £17 and £38 annually in NICE’s model, compared with £627.20 for fezolinetant.

FDA’s 2026 hormone therapy labelling changes may also rebalance competition. Greater acceptance of appropriate hormone treatment could expand the total treated population while limiting premium nonhormonal use among patients who can safely receive HRT. At the same time, increased public discussion of menopause may encourage previously untreated women to seek care, raising demand across both pathways.

 

Menopausal Hot Flashes Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 6.85 Billion
Revenue Forecast in 2032	USD 10.44 Billion
Overall Growth Rate	CAGR of 6.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Drug Class, By Route of Administration, By Application, By End User, By Distribution Channel, By Geography
By Treatment Type	Hormonal Therapies, Non-Hormonal Therapies
By Drug Class	Estrogen-Only Therapy, Estrogen–Progestogen Therapy, Neurokinin Receptor Antagonists, SSRIs and SNRIs, Anticonvulsants, Anticholinergic Drugs, Other Therapies
By Route of Administration	Oral, Transdermal, Topical, Intranasal
By Application	Natural Menopause-Related Vasomotor Symptoms, Treatment-Induced Vasomotor Symptoms
By End User	Hospitals, Gynaecology and Menopause Clinics, Primary Care Centres, Oncology Clinics
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of menopause-related vasomotor symptoms, increasing adoption of non-hormonal treatment options, growing awareness of menopause management solutions, expanding access to women’s healthcare services
Customization Option	Available upon request